未找到相关数据
Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)
被引：31
作者：
Atreya, Chloe Evelyn
Van Cutsem, Eric
Bendell, Johanna C.
Andre, Thierry
Schellens, Jan H. M.
Gordon, Michael S.
McRee, Autumn Jackson
O'Dwyer, Peter J.
Muro, Kei
Tabernero, Josep
van Geel, Robin
Sidhu, Roger
Greger, James G.
Rangwala, Fatima A.
Motwani, Monica
Wu, Yuehui
Orford, Keith W.
Corcoran, Ryan Bruce
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Univ Hosp Leuven, Leuven, Belgium
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Hop St Antoine, F-75571 Paris, France
[5] Netherlands Canc Inst, Amsterdam, Netherlands
[6] Pinnacle Oncol Hematol, Scottsdale, AZ USA
[7] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[8] Univ Penn, Philadelphia, PA 19104 USA
[9] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan
[10] Vall dHebron Univ Hosp, Barcelona, Spain
[11] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[12] Amgen Inc, Thousand Oaks, CA 91320 USA
[13] GlaxoSmithKline, Collegeville, PA USA
[14] GlaxoSmithKline, Res Triangle Pk, NC USA
[15] GlaxoSmithKline, Audubon, PA USA
[16] Massachusetts Gen Hosp, Boston, MA 02114 USA
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.103
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 [肿瘤学];
摘要：
103
引用
收藏
页数：1
相关论文